V aso-occlusive pain crisis (VOC) is the most common indication for hospitalization in children with sickle cell anemia (SCA), 1 accounting for an estimated 18,000 hospitalizations and 75,000 hospital days annually in the United States. 2 Treatments for VOC pain crisis are currently limited to symptomatic control with opioids and nonsteroidal antiinflammatory drugs.
Red blood cell (RBC) transfusions are frequently used to treat acute complications of SCA that may arise during VOC, including acute chest syndrome (ACS). 3 Little is known about RBC transfusion practices during hospitalizations for VOC. In the Cooperative Study of Sickle Cell Disease, the most common reasons for acute RBC transfusions in children with SCA were acute anemia, ACS, infection, and perioperative care. 4 A more recent investigation of RBC transfusions during sickle cell disease (SCD) hospitalizations, which was conducted via querying a multiinstitutional hospital discharge database, found that older age, male sex, and diagnosis of ACS and/or pneumonia or VOC were associated with a higher likelihood of transfusion. 5 RBC transfusions carry risks, including transfusion reactions and alloimmunization, so a better understanding of transfusion practices during hospitalizations for VOC is needed. As part of its Choosing Wisely campaign to decrease unnecessary testing and procedures, the American Society of Hematology specifically stated that RBC transfusions are not warranted for SCA patients with asymptomatic anemia during uncomplicated VOC. 6 Therefore, we undertook a secondary analysis of prospectively collected data from the multicenter Magnesium in Crisis (MAGiC) randomized controlled trial 7 to determine RBC transfusion patterns in children hospitalized with VOC. We hypothesized that RBC transfusion would be associated with a diagnosis of ACS, lower hemoglobin (Hb) concentration, and lack of hydroxyurea treatment.
MATERIALS AND METHODS
MAGiC was a randomized controlled trial conducted at eight academic pediatric hospitals in the United States through the Pediatric Emergency Care Applied Research Network (PECARN); the design, methods, and primary study results have been reported previously. 8 Briefly, eligible children were aged 4 to 21 years with SCA (HbSS or HbS-b 0 thalassemia) and were admitted to the hospital through the emergency department (ED) for treatment of VOC with intravenous opioids. Exclusion criteria included history of overt stroke, ACS diagnosis at the time of enrollment, other known cause for pain, discharge from inpatient unit for VOC within the preceding 3 days, more than 10 hospitalizations in the preceding year, chronic pain for which the child was prescribed daily opioids, or a RBC transfusion within the preceding 2 months. Children receiving hydroxyurea therapy were eligible, and children could participate during only one hospitalization. After enrollment, all medical complications including adverse events, ACS, and transfusions were abstracted daily from the medical record by study personnel. ACS was defined as ACS or pneumonia diagnosed by the subject's attending hematologist. Site ED and hematology investigators and clinical research assistants received education on identifying and diagnosing ACS. Presence or absence of ACS diagnosis or other adverse events was abstracted from subjects' medical records daily during hospitalization. Adverse events were defined as any untoward symptom or diagnosis experienced during the study period. Hydroxyurea therapy within the past 3 months was recorded as a categorical variable and was based on the child/parent report of hydroxyurea use. Opioid and nonopioid medications and RBC transfusions were prescribed according to each site's usual clinical practice. Hb concentration was obtained per each site's usual clinical practice during hospitalization. Hb values were recorded as absolute values from each blood draw and as change values from ED presentation.
Statistical analysis
Pearson's chi-square test was used to determine association between transfusions and ACS or other adverse events during hospitalization. Hb concentration was compared across groups with a t test, using the lowest pretransfusion Hb concentration for transfused subjects and the lowest Hb recorded during hospitalization for nontransfused subjects. Change in Hb values between lowest value and ED were also compared to determine whether transfusion practices were based on individual values or change in values. Relative risks (RRs) were calculated for variables of interest. Due to the collinear nature of the lowest Hb values and change in Hb from ED arrival, only the best predictor was carried forward in subsequent analyses. A binary recursive partitioning model using classification and regression tree (CART) analysis was performed to determine the predictors of receipt of a transfusion. Binary recursive partitioning is used in clinical research to identify decision trees to better understand clinical decisions. The analyses result in a tree that sequentially selects individual risk factors based on outcome prediction and then allow for the assessment of risk factors within specific subgroups of higher-and lower-risk subjects.
9,10 The level of significance was specified as p values of less than 0.05. There were no differences in any outcomes by treatment arm in the clinical trial, so both treatment arms were grouped together for these secondary analyses. Statistics were performed with software (SAS, Version 9.3, SAS Institute; CART Salford Predictive Modeler v7.0, Salford Systems).
RESULTS
Of the 204 subjects enrolled, 49% were male; 190 (93%) had HbSS disease and 14 (7%) had HbS-b 0 thalassemia. The mean age at enrollment was 13.6 years (standard deviation [SD], 4.7 years). Forty children (19.6%) received RBC transfusions during hospitalization; of these 40 children, 22 (55%) were diagnosed with ACS during hospitalization. A comparison of demographic factors and clinical events between transfused and nontransfused patients is shown in Table 1 . Children with a history of prior ACS (87.5% vs. 72%, p 5 0.04) were more likely to receive a transfusion during the hospitalization. Children who received transfusions had both a lower median ED Hb concentration (7.8 g/dL vs. 8.7 g/dL, p < 0.01) and median lowest Hb during hospitalization (6.3 g/dL vs. 8 .0 g/dL, p < 0.01), as well as a higher median ED white blood cell (WBC) count (15.5 3 10 9 /L vs. 13.3 3 10 9 /L, p 5 0.048). They were also more likely to have fever (47.5% vs. 21.3%, p < 0.01) and hypoxia, measured by pulse oximetry (22.5% vs 7.9%, p < 0.01).
ACS diagnosis during the hospitalization was strongly associated with RBC transfusion. Of children who were diagnosed with ACS during the hospitalization, 22 of 30 (73.3%) received a transfusion compared to 18 of 174 (10.3%) without a diagnosis of ACS; the RR of transfusion in children with ACS during hospitalization was 7.1 (95% confidence interval [CI], 4.4-11.5) compared to children without ACS (Table 2 ). Figure 1 , which is stratified by ACS diagnosis, shows the lowest Hb values and receipt of transfusions for each subject. Furthermore, we evaluated whether subjects with ACS received transfusions according to the recommendations of the National Heart, Lung, and Blood Institute's 2014 Expert Panel Report entitled "Evidence-Based Management of Sickle Cell Disease." This report strongly recommends transfusion if oxygen saturations are less than 90% despite supplemental oxygen and weakly recommends transfusion if Hb concentrations drop by 1 g/dL or more during ACS episodes. 11 There was not a significant difference between the transfused and nontransfused subjects with ACS for either variable. Specifically, 37.8% of transfused subjects had decreased oxygen saturations (as a binary variable) compared with 12.5% of nontransfused subjects (RR, 1.28; 95% CI, 0.87-1.89). Similarly, 59.1% of transfused subjects and 62.5% of nontransfused subjects had a drop in Hb concentration of 1 g/dL or more from their ED Hb concentration (RR, 0.96; 95% CI, 0.62-1.49). Because the RR of transfusion due to ACS was so strong, all other analyses were conducted on those without ACS to better understand that population. In bivariable analysis, the RR of transfusion was 3.1 for every 1 g/ dL decline in lowest Hb concentration (95% CI, 2.0-4.7). Lowest Hb was more strongly associated with transfusion than change from ED Hb to lowest Hb during hospitalization and hydroxyurea use in the past 3 months (Table 2) . There was no difference in the RR of transfusion for assigned treatment arm of magnesium versus placebo infusions (RR, 1.3; 95% CI, 0.5-3.2).
Among subjects without ACS, we compared hospital length of stay (LOS) stratified by transfusion status. Transfusion in subjects without ACS was associated with a significantly longer median LOS, 4.6 days (interquartile range [IQR], 3.2-8.3 days) compared with 2.1 days (IQR, 1.2-4.0 days) in the nontransfused subjects without ACS (p < 0.0001).
CART analysis (Fig. 2 ) also identified the development of ACS to be the strongest predictor of transfusion. Among those who developed ACS, 73% received transfusions. Excluding those with ACS, CART analysis showed that a lowest recorded Hb of less than 6.3 g/dL was most strongly predictive of transfusion, with 14 of 33 (42%) receiving transfusions, compared to four of 144 (3%) receiving transfusions if the Hb never decreased to less than 6.3 g/dL.
DISCUSSION
Approximately one in five children admitted to the hospital for a pain crisis during participation in the MAGiC trial received RBC transfusions during their hospitalization. Children diagnosed with ACS, the strongest predictor of transfusion, were more than seven times more likely to receive RBC transfusions during hospitalization. For those without ACS, a Hb concentration of less than 6.3 g/dL was most strongly associated with transfusion. To our knowledge, this is the only prospective analysis of transfusion practices in children with SCD hospitalized for VOC.
In the Cooperative Study of Sickle Cell Disease's infant cohort, 35% of enrolled children with HbSS disease received a blood transfusion by age 5 years. The most common reason for acute transfusion was acute anemia including splenic sequestration in 34.6%, followed by ACS in 27.5% and infection in 9.8%. 4 Because MAGiC only enrolled children with an uncomplicated VOC at the time of ED presentation, it more accurately reflects the treatment of children who present with VOC. In the only prior report of transfusion practices specifically among hospitalized children with SCD, Raphael and colleagues 5 found an increasing proportion of children with SCD received a RBC transfusion during hospitalization over time, from 14.2% in 1997 to 28.8% in 2009. They identified ACS or VOC diagnoses as modestly associated with increased likelihood of RBC transfusions. Their study encompassed tens of thousands of inpatients through a national hospitalization database, but it was limited by the lack of laboratory and pharmacy data, and thus they could not HULBERT ET AL.
determine the effects of Hb concentration or hydroxyurea therapy on the likelihood of transfusions. The study could not differentiate those who had ACS at admission versus those who were admitted with pain and developed ACS during hospitalization. Furthermore, given the anonymized nature of the database, they were unable to exclude children who received transfusions while inpatient as part of a chronic transfusion therapy program. Because MAGiC collected all clinically ordered Hb values and excluded chronically transfused children, our study gives a more detailed representation of RBC transfusions during acute VOC hospitalizations. Surprisingly, among MAGiC study participants, those treated with hydroxyurea were not less likely to receive a RBC transfusion. In contrast, in randomized controlled trials of hydroxyurea therapy, children and adults on hydroxyurea therapy were less likely to receive RBC transfusions. 12, 13 There are several potential explanations for this difference. First, subjects in MAGiC were classified as receiving hydroxyurea if they had taken it within the past 3 months, and adherence to and current receipt of hydroxyurea were not determined. Hydroxyurea's hematologic benefits increase with daily administration at maximum tolerated dose, 14 which was not captured in this definition. Second, MAGiC only included children who were ill enough to be hospitalized. It is possible that, while hydroxyurea therapy prevents hospitalizations, 12,13 it may not be as protective against transfusion once hospitalization occurs. The MAGiC study was not designed to identify differences in outcomes in children receiving hydroxyurea, so this finding should be interpreted cautiously. RBC transfusions can have benefits for people with SCD, especially during acute illness. In children and adults with ACS, RBC transfusions are frequently prescribed. 3 We did not detect a significant association with two variables recommended for prescribing RBC transfusions in ACS, oxygen saturations of less than 90% despite supplemental oxygen or Hb decrease of 1 g/dL or more. 11 This analysis is limited because MAGiC did not collect the amount of supplemental oxygen that patients received. Furthermore, this numerical approach to transfusions in patients with ACS may not capture other clinical factors influencing clinicians' transfusion decisions, such as degree of respiratory distress, rapidity of symptom progression, or extent of pulmonary infiltrates on chest x-ray. We identified an association between transfusion and longer LOS among non-ACS subjects. This may reflect a preference among some clinicians to give RBC transfusions to patients with longer or more severe pain crises, as well as the fact that therapy options for SCD patients remain limited. While chronic RBC transfusion therapy can prevent VOCs, [15] [16] [17] 20 This is consistent with the finding of acute silent cerebral ischemic events during acute severe anemia, defined as Hb concentration of 5.5 g/dL or less and at least 30% below baseline Hb, in children with and without SCA. 21 Thus, severe anemia during acute illness and resultant impairment of oxygen delivery to critical tissues can have significant consequences, but optimal transfusion thresholds have not been studied prospectively. Balancing the benefits of RBC transfusion with the risks is a critical task for hematologists and other physicians caring for children and adults with SCD, but there are no available tools to identify the patients at highest risk for sequelae of acute anemia or for complications of transfusions. Collecting prospective data on transfusion indications, Hb concentration before transfusion, and transfusion outcomes including RBC alloimmunization are necessary first steps. Development and validation of tools to support clinicians' decision making about transfusions, such as a tool to predict ACS severity and outcomes, 22 should follow so that transfusions are prescribed when the benefits outweigh the risks. This study has some limitations. First, the analysis of RBC transfusions during hospitalization is a secondary analysis, and the study was not designed to find differences in outcomes between transfused and nontransfused patients. Second, while laboratory data and any additional diagnoses were collected on each enrolled participant, the ordering physician's reason for transfusion was not collected; therefore, we can only report diagnoses or clinical events associated with RBC transfusion. It is possible that the transfused subjects had symptomatic anemia, aplastic crisis, or end-organ compromise such as splenic sequestration that were not captured by the study's data collection. Finally, data on alloimmunization were not collected. Some subjects may have had existing alloimmunization that would have affected transfusion decisions; additionally, subjects who were transfused could have developed subsequent alloimmunization, an important outcome of transfusion. The design of MAGiC did not include investigation of these potential issues. Nonetheless, its strengths, namely, the prospective design and uniform study population of children hospitalized with VOC, provide important insights into factors associated with RBC transfusions during acute VOC.
In conclusion, among subjects enrolled in MAGiC, approximately 20% of children admitted for an acute sickle cell pain crisis received a RBC transfusion. A diagnosis of ACS was the predominant risk for transfusion. Among those who did not develop ACS, lowest Hb concentration of less than 6.3 g/dL was the predominant risk factor for transfusion. Further work is needed to determine the frequency with which clinicians give RBC transfusions based solely on low Hb concentrations. Furthermore, there is a need for tools to assist clinicians deciding whether to prescribe RBC transfusions for children and adults hospitalized with SCA complications, including VOC.
